Gastrointestinal Cancer | Specialty

The OncLive Gastrointestinal Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of gastrointestinal (GI) cancers, including hepatocellular carcinoma, gastric cancer, pancreatic cancer, colorectal cancer, cholangiocarcinoma, esophageal cancer, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in GI cancers.

2025 Giants of Cancer Care: OncLive® Honors 13 Cancer Care Pioneers

June 30th 2025

OncLive® showcases 13 cancer care pioneers, who have won the 2025 Giants of Cancer Care award.

FDA Grants Breakthrough Therapy Designation to Daraxonrasib for KRAS G12X-Mutant Metastatic PDAC

June 29th 2025

Daraxonrasib earned FDA breakthrough therapy designation for previously treated metastatic PDAC harboring KRAS G12X mutations.

The OncFive: Top Oncology Articles for the Week of 6/22

June 28th 2025

The FDA grants approval to Dato-DXd in EGFR+ NSCLC, revumenib sNDA is under priority review for NPM1-mutant AML, and more from OncLive this week.

Elraglusib Plus Chemotherapy Extends OS vs Chemotherapy Alone in Frontline Metastatic PDAC

June 27th 2025

Elraglusib plus gemcitabine and nab-paclitaxel lead to an OS benefit vs chemotherapy alone in treatment-naive metastatic PDAC.

Treating Patients With Gastrointestinal Stromal Tumors

June 27th 2025

Panelists discuss how patient adherence to kinase inhibitors is crucial for disease control, requiring proactive adverse effect management, careful radiological monitoring, and strategies such as dose escalation to maximize treatment duration and effectiveness.

Gastrointestinal Stromal Tumor Treatment Landscape

June 27th 2025

Panelists discuss how standard-of-care treatment follows NCCN guidelines with sequential kinase inhibitor therapy (imatinib, sunitinib, regorafenib, ripretinib), emphasizing that maintaining some form of kinase inhibition is always preferable to no treatment even after progression.

Satri-Cel NDA Gets Go-Ahead From NMPA in Pretreated CLDN18.2+ Advanced Gastric/GEJ Cancer

June 26th 2025

The NMPA of China has accepted the new drug application for satricabtagene autoleucel in pretreated gastric/GEJ cancer.

Dr Reni on the Efficacy of Preoperative PAXG in Stage I to III PDAC

June 26th 2025

Michele Reni, MD, discusses the efficacy of pre-operative PAXG compared with modified FOLFIRINOX in stage I to III PDAC.

Explaining the Continued Interest in RAS Inhibition for PDAC

June 26th 2025

Mike J. Pishvaian, MD, PhD, and Martin Dietrich, MD, PhD, detail the continued interest in RAS inhibition for pancreatic ductal adenocarcinoma.

Dr Janjigian on the Efficacy of Durvalumab Plus Chemotherapy in Resectable GEJ Adenocarcinoma

June 24th 2025

Yelena Y. Janjigian, MD, discussed results from the MATTERHORN study of durvalumab plus FLOT in resectable gastric/gastroesophageal junction cancer.

Five Under 5: Top Oncology Videos for the Week of 6/15

June 22nd 2025

The top 5 OncLive videos of the week cover insights in CLL, multiple myeloma, follicular lymphoma, and extrapulmonary neuroendocrine carcinomas.

CHMP Recommends EU Approval of Cabozantinib for Pancreatic and Extra-Pancreatic Neuroendocrine Tumors

June 20th 2025

The EMA’s CHMP has recommended the approval of cabozantinib for patients with pancreatic and extra-pancreatic neuroendocrine tumors.

Role of Mutations in Gastrointestinal Stromal Tumors

June 20th 2025

Panelists discuss how mutational testing is critical for gastrointestinal stromal tumor (GIST) management, with different genetic alterations determining treatment sensitivity and the importance of understanding both primary drivers and secondary resistance mutations that develop over time.

Overview of Gastrointestinal Stromal Tumors

June 20th 2025

Panelists discuss how gastrointestinal stromal tumors (GISTs) are the most common sarcoma with specific genetic mutations, requiring comprehensive mutational analysis to guide treatment decisions and understand both primary and secondary resistance patterns.

GI Cancer Experts on Notable Updates Shared During the 2025 ASCO Annual Meeting

June 19th 2025

Expert investigators in GI cancers share their perspectives on the most significant updates in the space shared during the 2025 ASCO Annual Meeting.

Atebimetinib Plus Chemo Displays Potential Survival Benefit in First-Line Pancreatic Cancer

June 18th 2025

Atebimetinib plus gemcitabine/nab-paclitaxel produced signals of survival benefits in first-line pancreatic cancer.

Dr Elimova on the Efficacy of Zanidatamab With Chemotherapy in HER2+ Advanced/Metastatic Gastroesophageal Adenocarcinoma

June 14th 2025

Elena Elimova, MD, discusses the efficacy of zanidatamab with chemotherapy in HER2-positive advanced gastroesophageal adenocarcinoma.

FDA Grants Fast Track Designation to CHM CDH17 for Gastroenteropancreatic NETs

June 12th 2025

CHM CDH17 has received fast track designation from the FDA for the treatment of patients with gastroenteropancreatic neuroendocrine tumors.

Preliminary Casdozokitug Activity in HCC Supports Further Exploration of IL-27 as a Treatment Target

June 9th 2025

Daneng Li, MD, discusses the IL-27–targeted agent casdozokitug in hepatocellular carcinoma.

Casdozokitug Plus Atezolizumab/Bevacizumab Yields Antitumor Activity in Unresectable, Advanced HCC

June 5th 2025

Daneng Li, MD, discusses the efficacy and safety findings of a casdozokitug-based regimen in unresectable, advanced HCC.